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Abstract 
Background: A case-control association study was conducted to investigate a possible 
involvement of polymorphisms of three renin-angiotensin system genes (ACE - I/D and 
T-3892C, AGT - M235T and T174M, AT1R - A1166C) in the early development of 
hypertension. 
Methods: One hundred and twenty five hypertensive and 119 normotensive participants 
aged 18-40 were selected from a broader sample representative of the general 
population of Croatia. The selection criteria for hypertensive cases were systolic blood 
pressure higher than 140 mmHg and/or diastolic blood pressure higher than 90 mmHg 
and a history of hypertension according to patient interview.  
Results: Among the polymorphisms investigated, only those located on the ACE gene 
were associated with hypertension. For ACE I/D, the odds ratio for hypertension of DD 
versus II homozygote individuals was 2.50 (95% CI 1.19 to 5.25) and for ACE T-
3892C, the odds ratio of CC versus TT individuals was 2.32 (95% CI 1.05 to 5.10). Both 
polymorphisms of the ACE gene were in tight linkage disequilibrium. Out of the 
investigated risk factors for hypertension, only the body mass index showed an 
influence on the early development of hypertension, acting independently of the ACE 
polymorphism. Their additive effect gives rise to 86 % of hypertensives in subjects 
having both the DD genotype and BMI ≥ 30 kg/m2. 
Conclusions: The present study provides evidence of the association of the ACE gene 
polymorphisms and premature hypertension. Additionally, BMI proved to be another 
important predictor of the disorder acting independently of the ACE gene.  
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Introduction 
Hypertension is a complex disorder that represents one of the most important risk 
factors for myocardial infarction, stroke, end-stage renal disease and peripheral vascular 
disease 1. It is influenced by both environmental as well as by genetic factors. The 
genetic contribution is estimated to be between 30% and 40% of blood pressure 
variation 2,3. Several susceptibility genes for hypertension showing Mendelian 
inheritance have been identified to date 1, but their contribution to blood pressure 
variation in the general population is very small. Searching for genes that contribute to 
the complex form of hypertension has been much less successful. In recent years, a 
series of genes have been proposed to influence blood pressure and the evidence of the 
association with hypertension has been shown for some of them 4-6. However, these 
associations were not always confirmed 7-9. 
Genes encoding components of the renin-angiotensin system (RAS) have been proposed 
as candidate genes for hypertension since RAS is a well-known pathophysiological 
pathway involved in blood pressure regulation. RAS genes encoding angiotensinogen 
(AGT), angiotensin-1-converting enzyme (ACE) and angiotensin II type 1 receptor 
(AT1R) have been extensively studied and their involvement in the development of 
hypertension has been analyzed by linkage and association studies in various 
populations 4-11.  
The most extensively studied polymorphism in the ACE gene is the Alu insertion 
polymorphism (ACE I/D) in intron 16 of the gene, which is known to be associated with 
plasma ACE level 12,13. The ACE I/D polymorphism is presumed to be in linkage 
disequilibrium with functional variant that determines ACE plasma level 14 . However, 
in spite of a great number of polymorphisms detected in ACE gene – including the T-
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3892C polymorphism in the DNA upstream of the gene 15 – the functional variant has 
not yet been identified. Although there is strong evidence that there is a variant in the 
ACE gene that influences ACE plasma level, the available data on ACE gene influence 
on the development of hypertension are conflicting 5,8,16. However, two large 
population-based studies found linkage evidence and significant association of I/D with 
hypertension which was restricted to males 5,17. Moreover, strong evidence for a 
quantitative-trait locus for blood pressure on chromosome 17, which was close to the 
ACE gene, was found by a genome-scan analysis 18. 
The potential role of AGT gene in hypertension was originally explored by Jeunemaitre 
et al. 4. Among the 15 molecular variants of AGT that had been identified, significant 
association with hypertension was observed with 2 amino acid substitutions – M235T 
and T174M. The results of subsequent studies that tried to detect an association between 
these two variants and hypertension have been contradictory e.g. 7,10. 
The polymorphism A1166C in the 3’ untranslated region of the AT1R gene was detected 
by Bonnardeaux et al. 6 who also identified its association with hypertension. 
Subsequent studies yielded conflicting results e.g. 9.  
In the present case-control study we examined possible associations between 
polymorphisms of the AGT, ACE and AT1R genes and hypertension in the Croatian 
population under 40 years of age. Being aware of the composite nature of hypertension 
with the cumulative effects of environmental risk factors in the course of life we chose a 
sample of relatively young adults assuming that the genetic influence on hypertension 
might be more clearly detected. We studied I/D and T-3892C polymorphisms in ACE 
gene, M235T and T174M in AGT gene, and A1166C in AT1R gene.  
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Methods 
Study population 
The study sample was extracted from a broader sample of 10,074 participants that 
was collected from 1995 to 1996 within the subproject “Health Promotion” included in 
the First Croatian Health Project 19. The participants were adult volunteers aged 18-80 
from 30 randomly selected settlements belonging to all four major geographical regions 
of Croatia. A stratified multistage sampling design was used that provided the sample 
with a known probability distribution for variables age and sex. The age group of 18-40 
numbered 4115 participants, which was 2.6 % of the population of Croatia falling in 
that age range (according to the 1991 census). From all hypertensive participants aged 
18-40 yrs, 119 cases were selected randomly for the purpose of this study. The control 
group (N = 125) was chosen by matching cases with respect to age, sex and place of 
residence.  
Our criteria for selection of hypertensive participants were the following: 1. blood 
pressure greater than 140 mmHg for systolic pressure and/or 90 mmHg for diastolic 
pressure and 2. history of hypertension as assessed by patient interview. The inclusion 
of persons suffering from secondary hypertension was minimized using detailed health 
questionnaire. 
Arterial blood pressure (systolic and diastolic) was measured twice and the lower value 
was taken into account. The measurement was performed on the left upper arm by 
auscultation method after the subject had been seated for at least 15 minutes. Mercurial 
sphygmomanometers were used and the appropriate adult cuff size (medium or large) 
was applied. 
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Body height and weight were measured according to the IBP protocols 20 and used to 
calculate body mass index (BMI = weight (kg) / height2 (m2)). Data on blood 
triglycerides and cholesterol levels were also available 19. Basic characteristics of the 
sample are shown in Table 1. All the participants gave their informed consent. 
 
DNA analysis 
Samples of venous blood were collected in EDTA tubes for extraction of DNA from 
whole blood by using salting out procedure. 
Genotyping of the ACE I/D polymorphism was performed after polymerase chain 
reaction amplification of the region encompassing the polymorphism with 3 primers as 
described by Harrap 21 and detection of fragments on 2 % agarose gel. The genotypes of 
T-3892C in ACE gene, M235T and T714M polymorphisms in AGT gene and A1166C 
polymorphism in the AT1R gene were detected by allele-specific oligonucleotide 
hybridization as described previously 15,22,6. 
 
Statistical analysis 
For each polymorphism, allele frequencies were calculated from genotype frequencies 
in cases and controls. Deviation from Hardy-Weinberg equilibrium was assessed by χ2-
test with 1 df. In the control group, χ2-test was also used to test the differences in 
genotype distributions among four geographical regions of Croatia. Since no 
statistically significant differences were found, we assumed the homogeneity of 
Croatian population with respect to polymorphisms studied, and further analyses were 
carried out on total samples of cases and controls. Differences in genotype and allele 
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distributions between cases and controls were tested by χ2-test with 2 df and 1 df 
respectively.  
In order to compare the prevalence of hypertension among the genotypes of each 
polymorphism, genotypic odds ratios for hypertension were estimated using logistic 
regression analysis. The same analysis was used in order to calculate odds ratios for 
combined effects of sex, age, body mass index (BMI), triglycerides and cholesterol 
blood concentrations and genotypes on hypertension. BMI was compared across 
genotypes by univariate analysis of variance. 
Pairwise linkage disequilibrium (LD) was estimated as 1111 qpPD −= , where 11P  is the 
frequency of haplotype A1B1, and p1 and q2 are the frequencies of alleles A1 and B1 at 
loci A and B, respectively. The value of LD was expressed as Lewontin’s coefficient 23. 
Haplotype frequencies were estimated by expectation-maximization algorithm 24.  
A value of p ≤ 0.05 was considered statistically significant for all statistical tests. 
 
Results 
Genotype distributions of all five studied polymorphisms were compatible with Hardy-
Weinberg expectation in cases as well as in controls. Differences between cases and 
controls in genotype distributions were observed for both ACE gene polymorphisms 
(Table 2) with DD genotype of I/D polymorphism and CC genotype of T-3892C 
polymorphism being more prevalent in cases than in controls. Genotype distributions of 
other polymorphisms investigated in AGT and AT1R genes did not differ between these 
two groups. The difference in allele distributions was only observed for ACE ID with 
the D allele being more frequent in cases (56.7 % versus 45.5 % in controls).  
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To test the association of ACE gene polymorphisms with hypertension, genotypic odds 
ratios were calculated. Taking the II genotype of the ACE ID polymorphism as a 
reference, the odds ratio for hypertension associated with the ID genotype was 0.97 (95 
% confidence interval (CI) 0.51 – 1.83) and the odds ratio associated with the DD 
genotype was 2.50 (95 % CI 1.19 – 5.25), indicating a recessive effect of the D allele on 
risk (Table 3). A similar situation was observed for the T-3892C polymorphism in the 
ACE gene. Taking TT genotype as a reference, the odds ratio for hypertension 
associated with the CT genotype was 0.82 (95 % CI 0.47 – 1.45) and that associated 
with the CC genotype was 2.32 (95 % CI 1.05-5.10).  
The linkage disequilibrium (LD) between the two studied polymorphisms in the ACE 
gene was expressed as Lewontin’s coefficient D’ was –0.85. Such a high LD between 
two polymorphisms having similar allele frequencies suggests that their association 
with hypertension may have the same source that might possibly be a third 
polymorphism in LD with the ones investigated.  
The odds ratio associated with the combination of DD and CC genotypes versus all 
other combinations was 2.57 (95 % CI 1.20 – 5.52) i.e. very similar to the one observed 
in the separate analyses of these two polymorphisms (Table 3). 
In order to unravel the possible influence of several risk factors for hypertension - sex, 
age, body mass index and triglyceride and cholesterol concentrations – on the 
development of hypertension in the sample, these factors were incorporated as 
independent variables in the multivariate logistic regression together with ACE ID 
genotypes (Table 4). Beside the DD genotype that had in the univariate analysis already 
been shown as significant predictor for the presence of hypertension, the multivariate 
analysis revealed BMI as another significant predictor (OR 1.15 with 95 % CI 1.07 – 
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1.23). In order to check for independent influence of BMI and ACE on hypertension, the 
distribution of BMI was tested across the ACE genotypes. The univariate F of 0.274  for 
controls (d.f. = 2 and 118; p = 0.761) and 0.001 for cases (d.f. = 2 and 115; p = 0.999) 
indicated there were no differences in BMI distributions among the genotypes within 
each group. 
The relationship between BMI and hypertension across ACE ID genotypes is illustrated 
in Figure 1 where BMI is shown as a categorical variable with the cut-off point of 30 
kg/m2 that divides non-obese and obese subjects 25. The proportions of hypertensives 
across BMI and genotype clearly indicate the additive effect of obesity and ACE DD 
genotype. In non-obese ACE II and ID groups, the proportions of hypertensive cases are 
at the 40 % level. In the obese with these genotypes, the proportions increase up to the 
level found in the non-obese DD group (60 %). The proportion of hypertensives is as 
high as 86% in the obese DD group. 
 
Discussion 
In this study, we performed an association analysis of hypertension with polymorphisms 
in genes encoding components of the renin-angiotensin system in a general population 
sample from Croatia younger than 40 years of age. We chose to sample younger persons 
in order to enhance the detection of the genetic influence on hypertension assuming a 
stronger genetic component if the affected individuals are of a younger age. Since case-
control studies may suffer from several biases that may lead to false-positive and false-
negative results, we have matched our case and control groups for age, sex and place of 
residence, thus minimizing the biases. 
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Among the three RAS genes, we found that only the polymorhisms in ACE gene 
showed an association with hypertension. The association of DD genotype of ACE I/D 
polymorphism suggested the recessive effect of this susceptibility allele on the risk. A 
similar association was observed for the -3892 CC genotype. As these two 
polymorphisms are in strong LD, the association observed for each genotype separately 
probably reflects the same mechanism.  
Despite the strong evidence from both association and linkage studies that the ACE D 
allele influences ACE plasma levels 12,13, the data on its association with hypertension 
as well as on increased angiotensin II (potent vasoconstrictor molecule) levels are 
contradictory 5,8,16,17,21,26. However, ACE may also influence blood pressure regulation 
through the degradation of bradikinin, a strong vasodilatator and suppressor of smooth 
muscle cell growth. Some studies have shown that bradikinin concentration is decreased 
in hypertension 27 and Brown et al., 1998 28 have reported an association of the ACE D 
allele with increased degradation of bradykinin. 
The lack of association between ACE polymorphisms and hypertension in initial studies 
8,29 led to the opinion that ACE polymorphisms are not involved in the pathogenesis of 
hypertension. Recently, however, two large population-based studies found the 
evidence of both linkage and significant association of the I/D polymorphism with 
hypertension, which were restricted to male subjects only 5,17. Furthermore, a genome-
scan analysis revealed strong evidence of a quantitative-trait locus for blood pressure on 
chromosome 17 in the proximity of ACE gene 18. 
Our negative findings on the association of the polymorphisms in other two studied 
genes with hypertension is in accordance with some of the recently published papers 
e.g.7,9,10
. Jeunemaitre 30 states that such findings may result from the small sample sizes 
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that lack the statistical power to detect differences. The same remark may generally be 
applied to this study. The lack of association of the polymorphisms in AGT and AGT1R 
genes with hypertension may likewise be the consequence of the small sample size.  
Among the several known risk factors for hypertension (sex, age, body mass index, 
triglyceride and cholesterol blood concentrations), BMI was the only significant 
predictor for the presence of hypertension. The DD genotype and BMI seem to act 
independently on the development of hypertension since BMI distribution is the same 
regardless of ACE ID genotype.  
Finding of 86 % of hypertensives among the subjects having both DD genotype and 
BMI ≥ 30 kg/m2 – compared to 60 % of those having only one of these two risk factors 
and 40 % of those having neither of them – is consistent with an additive effect of DD 
genotype and obesity. Moreover, similar frequencies of obese and non-obese cases in 
both II and ID genotypes confirm the recessive nature of ACE ID polymorphism i.e. the 
influence of ACE ID on hypertension only in the case of the presence of two D alleles 
(Table 3, Figure 1).  
In conclusion, the present study detected the association of ACE gene polymorphsims 
with premature hypertension while no association with AGT and AT1R gene 
polymorphisms was obtained. Among several known risk factors for hypertension, BMI 
was the only one found to be associated with its development acting independently from 
the ACE gene.  
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Table 1.  Basic characteristics of study sample 
 Controls Cases 
N 125 119 
Male/Female 66/59 61/58 
Age (yrs) 34.82 ± 5.34 35.34 ± 5.28 
SBP (mm Hg) 124.82 ±10.95 150.22 ± 11.68 
DBP (mm Hg) 82.22 ± 9.15 96.24 ± 9.36 
BMI (kg/m2) 25.20 ± 3.85 27.53 ± 4.69 
Triglycerides (mmol/l) 1.67 ± 1.42 1.77 ±1.19 
Cholesterol (mmol/l) 5.57 ± 1.27 5.59 ± 1.27 
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Table 2.  Distributions of genotype and allele frequencies in cases and controls 
 Genotypes Alleles 
ACE IDa II (%) ID (%) DD (%) D (%) 
Controls 32 (26.0) 70 (56.9) 21 (17.1) 112 (45.5) 
Cases 25 (21.0) 53 (44.5) 41 (34.5) 135 (56.7) 
ACE T-3892Cb TT (%) TC (%) CC (%) C (%) 
Controls 42 (34.1) 68 (55.3) 13 (10.6) 94 (38.2) 
Cases 39 (32.8) 52 (43.7) 28 (23.5) 108 (45.4) 
AGT T174M CC (%) CT (%) TT (%) T (%) 
Controls 82 (68.9) 34 (28.6) 3 (2.5) 40 (16.8) 
Cases 75 (68.8) 27 (24.8) 7 (6.4) 41 (18.8) 
AGT M235T TT (%) TC (%) CC (%) C (%) 
Controls 36 (29.5) 56 (45.9) 30 (24.6) 116 (47.5) 
Cases 34 (31.8) 52 (48.6) 21 (19.6) 94 (43.9) 
AGTR A1166C AA (%) AC (%) CC (%) C (%) 
Controls 55 (47.8) 50 (43.5) 10 (8.7) 70 (30.4) 
Cases 48 (50.6) 33 (34.7) 14 (14.7) 61 (32.1) 
aSignificant difference in genotype and allele frequencies between cases and controls 
(p = 0.01; p = 0.02 respectively) 
bSignificant difference in genotype frequencies between cases and controls (p = 0.02) 
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Table 3. Odds ratios for the presence of hypertension by ACE ID and 
ACE T-3892C genotypes 
  OR 95 % CI 
ID versus II 0.97 0.51 – 1.83 
ACE ID 
DD versus II 2.50 1.19 – 5.25a 
TC versus TT 0.82 0.47 – 1.45 
ACE T-3892C 
CC versus TT 2.32 1.05 – 5.10b 
ACE ID  
and  
ACE T-3892C 
DD + CC versus all 
other combinations 
of genotypes on two 
loci 
2.57 1.20 – 5.52c 
Significance: a p = 0.02; b p = 0.03; c p = 0.02  
 
 
 
 22 
 
 
Table 4. Odds ratios for the presence of hypertension by ACE ID genotypes, sex, 
age, body mass index (BMI) and triglycerides and cholesterol blood 
concentrations 
 OR 95 % CI 
ID versus II 0.94 0.48 – 1.85 
ACE ID 
DD versus II 2.26 1.03 – 4.99a 
Sex 1.34 0.74 – 2.42 
Age (yrs) 0.99 0.94 – 1.05 
BMI (kg/m2) 1.15 1.07 – 1.23b 
Triglycerides (mmol/l) 1.04 0.81 – 1.34 
Cholesterol (mmol/l) 0.89 0.69 – 1.16 
Significance: a p = 0.04; b p = 0.001 
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Figure 1.  The frequency of cases and controls according to ACE ID genotype and 
BMI category.  
